Pre-metastatic niche

Last updated

A pre-metastatic niche is an environment in a secondary organ that can be conducive to the metastasis of a primary tumor. Such a niche provides favorable conditions for growth, and eventual metastasis, in an otherwise foreign and hostile environment for the primary tumor cells. This concept demonstrated the fundamental role of the microenvironment in regulating tumor growth and metastasis. The discovery of the pre-metastatic niche has fostered new research regarding the potential treatment of metastases, including targeting myeloid derived suppressor cells, and stromal cell plasticity including fibroblasts and pericytes and perivascular smooth muscle cells and (attempts to stop the flow of vesicles from primary tumors to pre-metastatic niches in secondary organs and different combinations of microenvironment targeted therapies.

Contents

Pre-metastatic niche formation

Tumors metastasize to particular organs due to the migration of hematopoietic bone marrow cells expressing VEGFR1 [1] (vascular endothelial growth factor receptor 1) [2] and stromal cells [3] [4] to these particular sites prior to the formation of clinically relevant metastasis. These cells along with changes in the extracellular matrix form pre-metastatic niches that support disseminated tumor cells and allow these cells to gather and more easily colonize the organ. Pre-metastatic niche formation is influenced by many different bodily processes, including the suppression of the immune system [5] and an increase in the presence of cytokines and other growth factors. [6] and extracellular matrix deposition and remodeling [7] Hypoxia in the primary tumor and the movement of exosomes from the primary tumor to the secondary organ are additional phenomena that are partially responsible for the formation of pre-metastatic niches. [6]

Role in metastasis

In order to metastasize, tumor cells should arrive at an organ with an environment conducive to their growth, such as a pre-metastatic niche. The creation of this environment is accomplished by factors from the primary tumor that alter the structure of the secondary organ in order to allow cells from the primary tumor to more easily colonize the secondary organ. [8] Tumor cells release factors that cause bone cells to resorb and therefore increase the rate of metastasis. Bone is conducive to the metastatic process given its composition of many different kinds of cells and its ability to grow skeletal structures. [9] Without the process of pre-metastatic niche formation, metastases are less likely to occur. There are often tumor cell deposits found in organs without a metastasis, indicating that metastases do not always proliferate in the tissues that they enter after leaving the circulatory system. [9]

Role of the immune system

Pre-metastatic niche formation is possible due in large part to active immune suppression. Primary tumors recruit myeloid derived suppressor cells, which are myeloid cells that can inhibit antigen presentation and T cells mediated cytotoxicity, in order to allow the tumor cells to avoid detection by the immune system as they metastasize, and thus allows the metastasis to flourish. As the primary tumors release tumor cells into the bloodstream, myeloid cells that have been recruited by the tumor, can protect the cancer cells from detection by the adaptive immune system, which would otherwise be halting metastasis. [5] Myeloid progenitor cells, recruited at various different stages in their cell development, are believed to constitute much of the pre-metastatic niche, as they can protect the tumor cells from the standard immune response as the cancer cells attempt to colonize the pre-metastatic niche. [5] Given their important role not only in protecting the growing metastasis from immune system attacks, but also in enabling extravasation, myeloid cells are a key factor in the development of the pre-metastatic niche, and thus eventually in promoting metastases.

Chemokines, a class of signaling molecules, also play a significant role in the creation of pre-metastatic niches and metastases. [10] The primary tumor, in an attempt to evade detection by the immune system, uses chemokines in order to increase recruitment of bone marrow-derived myeloid cells to secondary organs. In addition, cancer cells from the primary tumor can be used to induce inflammation in the future site of the pre-metastatic niche in the secondary organ, which is similar to the immune response created by an infection.

Thus, the large presence of immune cells allows the pre-metastatic niche to ward off attacks by the immune system and therefore allow the tumor to metastasize without inhibition. Immune suppression, combined with hypoxia and ECM, among other processes, are essential steps in allowing a primary tumor to metastasize, as they allow tumor cells to grow in a foreign and hostile environment without being destroyed by the typical response of the immune system. Specifically, necessary amino acids are depleted and lymphocyte movement is decreased while regulatory T cells, which suppress the immune system, and oxidative stress are increased. [6]

Discovery of the pre-metastatic niche

Metastasis has typically been condensed into a few simple steps, namely that the tumor cells leave the primary tumor and travel to secondary organs via the circulatory system in an attempt to invade the foreign environment of the pre-metastatic organ. Since tumor growth is often difficult in a new and relatively hostile environment, metastasis had been considered by many to be an inefficient process, despite its high mortality rate. Although Stephen Paget's previously established ‘seed and soil’ hypothesis correlates with the newer idea of primary tumor cells migrating to pre-metastatic niches, the focuses of many researchers are shifting from the primary tumor, given the assumed inevitability of metastasis in the presence of a tumor, to the secondary organs where metastases occur. The role of exosomes in priming organs for metastasis has only recently become a significant topic of conversation among researchers, due in large part to the discovery of tumor cells deposits in organs without metastases. [9] The concept of the pre-metastatic niche was discovered in David Lyden's laboratory, by Drs. David Lyden and Stergios Zacharoulis, and the pre-metastatic niche was first described and characterized by Drs. Rosandra Kaplan, Rebecca Riba, Stergios Zacharoulis et al., in 2005. [11]

Implications for cancer treatment

The recognition of the concept of the pre-metastatic niche allows researchers to consider several new possibilities for treating cancer. One such possibility is employing methods that attempt to limit the expression of VEGFR1 in cells, thereby combating metastasis by delaying the creation of or eradicating the pre-metastatic niche altogether. [1] Targeting hypoxia in the primary tumor and the suppression of the immune system could also stop the creation of pre-metastatic niches. [6] Factors from the primary tumor that structurally alter the secondary organ in order to facilitate its colonization by tumor cells could also potentially be targeted in an attempt to stop metastasis. [2]

Tumor cells grown in different microenvironments yield different types of protein, indicating that varying types of oncological treatments are needed for tumors in distinct locales. It is easier to target later stages of metastasis because cancer is often not found until the earlier stages of metastasis have been completed. Thus, a combination of primary therapies and drugs that combat metastasis could be used to arrest the colonization of a secondary organ by tumor cells, as this would stop both the cells flowing from the tumor and the formation of the pre-metastatic niche. Alternatively, using drugs to stop tumor cells from migrating to pre-metastatic niches could be an effective method of halting metastases. [9]

Related Research Articles

<span class="mw-page-title-main">Metastasis</span> Spread of a disease inside a body

Metastasis is a pathogenic agent's spread from an initial or primary site to a different or secondary site within the host's body; the term is typically used when referring to metastasis by a cancerous tumor. The newly pathological sites, then, are metastases (mets). It is generally distinguished from cancer invasion, which is the direct extension and penetration by cancer cells into neighboring tissues.

<span class="mw-page-title-main">Sarcoma</span> Medical condition

A sarcoma is a malignant tumor, a type of cancer that arises from transformed cells of mesenchymal origin. Connective tissue is a broad term that includes bone, cartilage, fat, vascular, or hematopoietic tissues, and sarcomas can arise in any of these types of tissues. As a result, there are many subtypes of sarcoma, which are classified based on the specific tissue and type of cell from which the tumor originates. Sarcomas are primary connective tissue tumors, meaning that they arise in connective tissues. This is in contrast to secondary connective tissue tumors, which occur when a cancer from elsewhere in the body spreads to the connective tissue. The word sarcoma is derived from the Greek σάρκωμα sarkōma "fleshy excrescence or substance", itself from σάρξsarx meaning "flesh".

<span class="mw-page-title-main">Selectin</span> Family of cell adhesion molecules

The selectins are a family of cell adhesion molecules. All selectins are single-chain transmembrane glycoproteins that share similar properties to C-type lectins due to a related amino terminus and calcium-dependent binding. Selectins bind to sugar moieties and so are considered to be a type of lectin, cell adhesion proteins that bind sugar polymers.

Intravasation is the invasion of cancer cells through the basement membrane into a blood or lymphatic vessel. Intravasation is one of several carcinogenic events that initiate the escape of cancerous cells from their primary sites. Other mechanisms include invasion through basement membranes, extravasation, and colonization of distant metastatic sites. Cancer cell chemotaxis also relies on this migratory behavior to arrive at a secondary destination designated for cancer cell colonization.

<span class="mw-page-title-main">E-selectin</span>

E-selectin, also known as CD62 antigen-like family member E (CD62E), endothelial-leukocyte adhesion molecule 1 (ELAM-1), or leukocyte-endothelial cell adhesion molecule 2 (LECAM2), is a selectin cell adhesion molecule expressed only on endothelial cells activated by cytokines. Like other selectins, it plays an important part in inflammation. In humans, E-selectin is encoded by the SELE gene.

<span class="mw-page-title-main">RANKL</span> Mammalian protein found in Homo sapiens

Receptor activator of nuclear factor kappa-Β ligand (RANKL), also known as tumor necrosis factor ligand superfamily member 11 (TNFSF11), TNF-related activation-induced cytokine (TRANCE), osteoprotegerin ligand (OPGL), and osteoclast differentiation factor (ODF), is a protein that in humans is encoded by the TNFSF11 gene.

<span class="mw-page-title-main">Metastatic liver disease</span> Medical condition

A liver metastasis is a malignant tumor in the liver that has spread from another organ affected by cancer. The liver is a common site for metastatic disease because of its rich, dual blood supply. Metastatic tumors in the liver are 20 times more common than primary tumors. In 50% of all cases the primary tumor is of the gastrointestinal tract; other common sites include the breast, ovaries, bronchus and kidney. Patients with Colorectal cancer will develop liver metastases during the disease

<span class="mw-page-title-main">Desmoplasia</span> Growth of fibrous or connective tissue

In medicine, desmoplasia is the growth of fibrous or connective tissue. It is also called desmoplastic reaction to emphasize that it is secondary to an insult. Desmoplasia may occur around a neoplasm, causing dense fibrosis around the tumor, or scar tissue (adhesions) within the abdomen after abdominal surgery.

<span class="mw-page-title-main">Bone metastasis</span> Medical condition

Bone metastasis, or osseous metastatic disease, is a category of cancer metastases that results from primary tumor invasion to bone. Bone-originating primary tumors such as osteosarcoma, chondrosarcoma, and Ewing's sarcoma are rare; the most common bone tumor is a metastasis Bone metastases can be classified as osteolytic, osteoblastic, or both. Unlike hematologic malignancies which originate in the blood and form non-solid tumors, bone metastases generally arise from epithelial tumors and form a solid mass inside the bone. Bone metastases, especially in a state of advanced disease, can cause severe pain, characterized by a dull, constant ache with periodic spikes of incident pain.

<span class="mw-page-title-main">Metastatic breast cancer</span> Type of cancer

Metastatic breast cancer, also referred to as metastases, advanced breast cancer, secondary tumors, secondaries or stage IV breast cancer, is a stage of breast cancer where the breast cancer cells have spread to distant sites beyond the axillary lymph nodes. There is no cure for metastatic breast cancer; there is no stage after IV.

<span class="mw-page-title-main">Brain metastasis</span> Cancer that has metastasized (spread) to the brain from another location in the body

A brain metastasis is a cancer that has metastasized (spread) to the brain from another location in the body and is therefore considered a secondary brain tumor. The metastasis typically shares a cancer cell type with the original site of the cancer. Metastasis is the most common cause of brain cancer, as primary tumors that originate in the brain are less common. The most common sites of primary cancer which metastasize to the brain are lung, breast, colon, kidney, and skin cancer. Brain metastases can occur in patients months or even years after their original cancer is treated. Brain metastases have a poor prognosis for cure, but modern treatments are allowing patients to live months and sometimes years after the diagnosis.

Lymph node metastasis is the spread (metastasis) of cancer cells into a lymph node.

Lewis lung carcinoma is a tumor that spontaneously developed as an epidermoid carcinoma in the lung of a C57BL mouse. It was discovered in 1951 by Dr. Margaret Lewis of the Wistar Institute and became one of the first transplantable tumors.

<span class="mw-page-title-main">Joan Massagué</span>

Joan Massagué, is a Spanish biologist and the current director of the Sloan Kettering Institute at Memorial Sloan Kettering Cancer Center. He is also an internationally recognized leader in the study of both cancer metastasis and growth factors that regulate cell behavior, as well as a professor at the Weill Cornell Graduate School of Medical Sciences.

<span class="mw-page-title-main">Tasquinimod</span>

Tasquinimod is an experimental drug currently being investigated for the treatment of solid tumors. Tasquinimod has been mostly studied in prostate cancer, but its mechanism of action suggests that it could be used to treat other cancers. Castration-resistant prostate cancer (CRPC), formerly called hormone-resistant or hormone-refractory prostate cancer, is prostate cancer that grows despite medical or surgical androgen deprivation therapy. Tasquinimod targets the tumor microenvironment and counteracts cancer development by inhibiting angiogenesis and metastasis and by modulating the immune system. It is now in phase III development, following successful phase II trial outcomes.

<span class="mw-page-title-main">Tumor microenvironment</span>

The tumor microenvironment (TME) is the environment around a tumor, including the surrounding blood vessels, immune cells, fibroblasts, signaling molecules and the extracellular matrix (ECM). The tumor and the surrounding microenvironment are closely related and interact constantly. Tumors can influence the microenvironment by releasing extracellular signals, promoting tumor angiogenesis and inducing peripheral immune tolerance, while the immune cells in the microenvironment can affect the growth and evolution of cancerous cells.

Patient derived xenografts (PDX) are models of cancer where the tissue or cells from a patient's tumor are implanted into an immunodeficient or humanized mouse. PDX models are used to create an environment that allows for the natural growth of cancer, its monitoring, and corresponding treatment evaluations for the original patient.

Breast cancer metastatic mouse models are experimental approaches in which mice are genetically manipulated to develop a mammary tumor leading to distant focal lesions of mammary epithelium created by metastasis. Mammary cancers in mice can be caused by genetic mutations that have been identified in human cancer. This means models can be generated based upon molecular lesions consistent with the human disease.

Cryoimmunotherapy, also referred to as cryoimmunology, is an oncological treatment for various cancers that combines cryoablation of tumor with immunotherapy treatment. In-vivo cryoablation of a tumor, alone, can induce an immunostimulatory, systemic anti-tumor response, resulting in a cancer vaccine—the abscopal effect. Thus, cryoablation of tumors is a way of achieving autologous, in-vivo tumor lysate vaccine and treat metastatic disease. However, cryoablation alone may produce an insufficient immune response, depending on various factors, such as high freeze rate. Combining cryotherapy with immunotherapy enhances the immunostimulating response and has synergistic effects for cancer treatment.

<span class="mw-page-title-main">Rosandra N. Kaplan</span> American pediatric oncologist and scientist

Rosandra N. Kaplan is an American pediatric oncologist and scientist specialized in translational and clinical research on the mechanisms of cancer spread. She is a principal investigator and head of the tumor microenvironment and metastasis branch at the National Cancer Institute.

References

  1. 1 2 "The 'pre-metastatic' niche : Nature". www.nature.com. Retrieved 2017-05-05.
  2. 1 2 Kaplan, Rosandra (2005-12-08). "VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche". Nature. 438 (7069): 820–827. Bibcode:2005Natur.438..820K. doi:10.1038/nature04186. PMC   2945882 . PMID   16341007.
  3. ↑ Kaplan, Rosandra (2016-03-16). "Activation of Hematopoietic Stem/Progenitor Cells Promotes Immunosuppression Within the Pre-metastatic Niche". Cancer Research. 23 (10): 1176–1190. doi:10.1038/nm.4400. PMC   5724390 . PMID   28920957.
  4. ↑ Liu, Yang; Cao, Xuetao (2016-11-14). "Characteristics and Significance of the Pre-metastatic Niche". Cancer Cell. 30 (5): 668–681. doi: 10.1016/j.ccell.2016.09.011 . ISSN   1535-6108. PMID   27846389.
  5. 1 2 3 Kitamura, Takanori; Qian, Bin-Zhi; Pollard, Jeffrey W. (February 2015). "Immune cell promotion of metastasis". Nature Reviews. Immunology. 15 (2): 73–86. doi:10.1038/nri3789. ISSN   1474-1733. PMC   4470277 . PMID   25614318.
  6. 1 2 3 4 Sceneay, Jaclyn; Smyth, Mark J.; Möller, Andreas (2013-12-01). "The pre-metastatic niche: finding common ground". Cancer and Metastasis Reviews. 32 (3–4): 449–464. doi:10.1007/s10555-013-9420-1. hdl: 11343/220045 . ISSN   1573-7233. PMID   23636348. S2CID   12170925.
  7. ↑ Murgai, Meera; Kaplan, Rosandra (2017). "KLF4-dependent perivascular cell plasticity mediates pre-metastatic niche formation and metastasis". Nature Medicine. 23 (10): 1176–1190. doi:10.1038/nm.4400. PMC   5724390 . PMID   28920957.
  8. ↑ Høye, Anette M.; Erler, Janine T. (2016-06-01). "Structural ECM components in the premetastatic and metastatic niche". American Journal of Physiology. Cell Physiology. 310 (11): C955–C967. doi: 10.1152/ajpcell.00326.2015 . ISSN   0363-6143. PMID   27053524.
  9. 1 2 3 4 Cox, Thomas R; Gartland, Alison; Erler, Janine T (2012-05-02). "The pre-metastatic niche: is metastasis random?". BoneKEy Reports. 1 (5): 80. doi:10.1038/bonekey.2012.80. ISSN   2047-6396. PMC   4816289 . PMID   27127624.
  10. ↑ Maru, Yoshiro (November 2015). "The lung metastatic niche". Journal of Molecular Medicine. 93 (11): 1185–1192. doi:10.1007/s00109-015-1355-2. ISSN   1432-1440. PMID   26489606. S2CID   6550269.
  11. ↑ "Lyden, David C". vivo.med.cornell.edu. Retrieved 2017-06-09.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.